• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home ENT

Improved overall survival with HPV positive oropharyngeal squamous cell carcinoma

byMonica ParksandAndrew Bishara
June 27, 2014
in ENT, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to HPV negative oropharyngeal squamous cell carcinoma, HPV positive tumors are associated with increased overall survival after progression of disease.

Evidence Rating Level: 2 (Good)

Study Rundown: Certain strains of human papillomavirus (HPV) are associated with oropharyngeal squamous cell carcinomas (OPCs), and HPV positive tumors have significantly reduced risk of cancer progression compared to HPV negative tumors. At the conclusion of this retrospective analysis, the authors found that positive HPV status was significantly associated with increased overall survival following local, regional or distant disease progression. Positive HPV tumor status and receipt of salvage surgery were both associated with reduced mortality after progression. Similar rates of and distribution of distant metastases were noted in both groups. Based on these results, the authors suggested that HPV status represents a significant prognostic marker in the evaluation of progressive oropharyngeal squamous cell carcinoma. However, it should be noted that the authors were unable to evaluate the effect of chemotherapy on overall survival. Furthermore, the HPV positive and negative groups had distinct demographic characteristics.

Click to read the study in JCO

Relevant Reading: Human papillomavirus and survival of patients with oropharyngeal cancer.

In-Depth [retrospective cohort study]: The authors of this retrospective analysis drew patient data from several phase III prospective clinical trials evaluating different radiotherapies in the treatment of confirmed oropharyngeal squamous cell carcinoma. A total of 181 patients were included, with 105 HPV positive and 76 HPV negative, and all had experienced local, regional, or distant disease progression. Multivariable analysis included HPV status, T stage at enrollment, progression type, salvage surgery, and pack years. The primary outcome was overall survival after disease progression. HPV positive patients were significantly more likely to be younger, Caucasian, report less cumulative cigarette exposure, and present initially with earlier tumor stages. The median time to disease progression was similar between the two groups (8.2 versus 7.3 months; p = 0.67). The mean follow-up time after progression was first noted was 4 years. On Kaplan-Meier analysis, HPV positive patients had significantly increased overall survival following progression compared to HPV negative patients (HR 0.49; 95% CI, 0.34-0.70, p < 0.001). HPV positive status (HR 0.48; 95% CI, 0.31 to 0.74) and receipt of salvage surgery (HR 0.48; 95% CI; 0.27 to 0.84) were both associated with reduced mortality after disease progression.

RELATED REPORTS

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

Pfizer’s Talzenna combo significantly delays prostate cancer progression

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: ENThpvoncologyoropharyngeal cancersquamous cell cancer
Previous Post

Novel aromatase inhibitor, ODM-201, may be safe and effective for prostate cancer

Next Post

Ultrasound, flow reserve guided coronary interventions provide minimal benefit

RelatedReports

Thoracic radiotherapy improves survival in small-cell lung cancer patients
Chronic Disease

Simvastatin (Zocor) in combination with paclitaxel (Taxol) may provide treatment benefit compared to paclitaxel alone for small cell lung cancer

April 15, 2026
Radiation plus hormone therapy may improve prostate cancer survival
Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Intrapartum serum prolactin may predict risk of postpartum diabetes
Chronic Disease

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

March 26, 2026
Next Post
Ultrasound, flow reserve guided coronary interventions provide minimal benefit

Ultrasound, flow reserve guided coronary interventions provide minimal benefit

Pre-operative transcranial magnetic stimulation useful for language mapping

Shunt settings may have little effect on intracranial pressure in hydrocephalus

Antepartum and intrapartum events both linked to neonatal HIE

Induction of labor more successful with standardization

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind April 27, 2026
  • Tenecteplase (TNKase) may worsen functional outcomes in older patients with minor ischemic stroke
  • Jennifer Aniston’s “Strength for 50+” ritual spotlights red light therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

The Classics in Medicine Paperback Released!

Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.

amazon-logo_blackGet-it-on-iBooks-badge

Click anywhere to close this announcement

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.